MediPharm Labs Prepares for Second Quarter Financial Results
MediPharm Labs Corp. (TSX: LABS, OTCQB: MEDIF, FSE: MLZ), a leading company in the production of high-grade cannabinoid products, is excited to announce that they will be unveiling their financial results for the second quarter on a scheduled basis. The results for the three and six months ending June 30, 2025, will be available to the public before the market opens on Thursday, August 14, 2025.
Details of the Financial Release
The executive team at MediPharm Labs will host a conference call and a webcast on the same day at 10:00 AM Eastern Time. This event will provide an opportunity for stakeholders and interested parties to engage with the management team and hear firsthand about the company's financial health and market strategies moving forward.
Conference Call Participation
To join the conference call, participants from North America can dial the toll-free number (888) 330-2454, while international participants can access the call at +1 (240) 789-2714. It is encouraged that participants call in approximately 15 minutes prior to the start time to ensure a smooth experience.
Webcast Details
For those who prefer to join online, a webcast is available on MediPharm’s official website. This will stream the call live, allowing investors and analysts to follow along with the presentation and potentially engage in the Q&A session following the reports. The recording of the webcast will also be available shortly after the live session.
About MediPharm Labs
Founded in 2015, MediPharm Labs focuses on the development and manufacturing of high-purity cannabis concentrates and pharmaceutical-grade products. The company operates in a Good Manufacturing Practices (GMP) certified facility, which is equipped to ensure the production of safe and reliable cannabinoid products. Utilizing innovative technologies along with their experienced research team, MediPharm Labs is positioned to deliver exceptional cannabinoid-based products to diverse markets.
Regulatory Compliance and Accreditations
In 2021, MediPharm Labs reached a milestone by obtaining a Pharmaceutical Drug Establishment License from Health Canada, making it the only company in North America with a commercial-scale GMP license for cannabinoid extraction. This achievement secures MediPharm's credibility and supports their ongoing efforts to register foreign drug manufacturing sites with the US FDA.
Recent Acquisition Enhances Market Reach
In a strategic move in 2023, MediPharm Labs acquired VIVO Cannabis Inc., significantly broadening their reach within the medical cannabis sector. This acquisition integrated additional distribution channels, including the Canna Farms ecommerce platform in Canada and partnerships with Beacon Medical in Australia and Germany. Furthermore, included in this acquisition were Harvest Medical Clinics, which provide valuable consultation services to medical cannabis patients in Canada.
Company Commitment
MediPharm Labs upholds the highest level of compliance in all jurisdictions it operates. Their dedication to quality and safety resonates with their mission to serve the medical cannabis community effectively. By maintaining rigorous standards and focusing on research-driven practices, MediPharm Labs continues to lead in the evolving cannabinoid market.
Frequently Asked Questions
What is the release date for MediPharm's second quarter financial results?
The financial results will be released on August 14, 2025, before the market opens.
How can I participate in the conference call?
Participants can join the conference by calling North America Toll-Free: (888) 330-2454 or International Toll: +1 (240) 789-2714.
Where can I find the webcast for the financial results?
The webcast will be available on MediPharm's official website during the conference call.
What is MediPharm Labs known for?
MediPharm Labs is known for specializing in the development and manufacture of high-quality cannabinoid extracts and pharmaceutical-grade cannabis products.
When was MediPharm Labs founded?
MediPharm Labs was founded in 2015 and has since specialized in cannabis-related pharmaceuticals.
